EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Enhanced External Counterpulsation Reduces the Risk of Early Cystatin‐C Rise in STEMI Patients After Primary PCI: A Single‐Center Randomized Controlled Clinical Trial

Chun-Mei Zeng iD, Guo-Qiang Liu, Hong Lin, Liang Cai, Cai-Zhong Huang, Gui-Qiong Mo, Xin-Jing Zhong iD

Cardiovascular Therapeutics · 2026-01 · 2026 (1)

DOI: 10.1155/cdr/4232591 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cardiovascular Therapeutics, online erschienen am 15.11.2026. Verfasst von Chun-Mei Zeng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiolog, Yulin First People's Hospital (The Sixth Affiliated Hospital of Guangxi Medical University), Yulin, Guangxi, China. Hauptthemen laut MEDLINE: Acute Kidney Injury, Counterpulsation, Cystatin C, Percutaneous Coronary Intervention. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangxi Health Care Commission Project: Efficacy of EECP for Preventing CI-AKI Post-Primary PCI in STEMI Patients.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the effect of enhanced external counterpulsation (EECP) on cystatin‐C in patients with ST‐elevation myocardial infarction (STEMI) following primary percutaneous coronary intervention (primary PCI).

Methods

A total of 436 STEMI patients who underwent primary PCI were enrolled and randomly assigned to the EECP group ( n = 211) and the control group ( n = 225). The control group received routine treatment alone, and the EECP group was additionally treated with EECP, which was initiated within 4–12 hours and lasted for up to 72 hours after PCI, with one to two sessions per day and 0.5–1 hour per session. Renal function indicators were detected in all patients before primary PCI, as well as at 24, 72 hours, and 5–7 days after PCI. The differences in renal function parameters, cystatin‐C, and the incidence of contrast‐induced acute kidney injury (CI‐AKI) were compared between the two groups.

Results

Compared with the control group, the EECP group presented significantly lower cystatin‐C at 24, 72 hours, and 5–7 days after PCI ( p < 0.01), lower serum creatinine (Scr) at 24 hours ( p = 0.045), and higher estimated glomerular filtration rate (eGFR) ( p = 0.025). Post‐PCI eGFR decreased markedly in the control group ( p < 0.001), whereas no significant difference was observed in the EECP group ( p = 0.361). The linear mixed‐effects model demonstrated a significant between‐group difference in cystatin‐C ( p < 0.0001), whereas neither the main time effect nor the group‐by‐time interaction reached statistical significance. Patients in the EECP group exhibited a lower risk of increased cystatin‐C (9.5% vs. 4.3%, χ 2 = 4.359, p = 0.037). Nevertheless, there was no statistically significant intergroup difference in the incidence of SCr‐defined CI‐AKI ( p = 0.584). Firth penalized logistic regression analysis revealed that EECP was an independent protective factor against elevated cystatin‐C (Model 1: OR = 0.45, 95% CI 0.19–0.96, p = 0.037; Model 2: OR = 0.44, 95% CI 0.19–0.94, p = 0.034).

Conclusion

EECP can reduce cystatin‐C rise after primary PCI in STEMI patients and can represent as a promising intervention targeting biomarkers of early renal injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Kidney InjuryCounterpulsationCystatin CPercutaneous Coronary InterventionST Elevation Myocardial InfarctionAgedFemaleHumansMaleMiddle AgedBiomarkersCreatinineRisk FactorsTime FactorsTreatment OutcomeUp-Regulation

Stichwörter der Autor:innen

CI-AKIEECPSTEMIcystatin Cprimary PCI

Substanzen

BiomarkersCreatinineCST3 protein, humanCystatin C

Autor:innen und Institutionen

  • Department of Cardiolog, Yulin First People's Hospital (The Sixth Affiliated Hospital of Guangxi Medical University), Yulin, Guangxi, China.
  • Guangxi Medical University, Nanning, Guangxi, China, gxmu.edu.cn.
  • Department of General Practice, Yulin First People's Hospital (The Sixth Affiliated Hospital of Guangxi Medical University), Yulin, Guangxi, China.

ORCID-Profile: Chun-Mei Zeng, Xin-Jing Zhong

Förderung

  • Guangxi Health Care Commission Project: Efficacy of EECP for Preventing CI-AKI Post-Primary PCI in STEMI Patients

Zitieren

APA

Zeng, C. M., Liu, G. Q., Lin, H., Cai, L., Huang, C. Z., Mo, G. Q., & Zhong, X. J. (2026). Enhanced External Counterpulsation Reduces the Risk of Early Cystatin‐C Rise in STEMI Patients After Primary PCI: A Single‐Center Randomized Controlled Clinical Trial. Cardiovascular Therapeutics, 2026(1). https://doi.org/10.1155/cdr/4232591

Vancouver

Zeng CM, Liu GQ, Lin H, Cai L, Huang CZ, Mo GQ, et al. Enhanced External Counterpulsation Reduces the Risk of Early Cystatin‐C Rise in STEMI Patients After Primary PCI: A Single‐Center Randomized Controlled Clinical Trial. Cardiovascular Therapeutics. 2026;2026(1). doi:10.1155/cdr/4232591

BibTeX
@article{Zeng2026,
  author = {Zeng, Chun-Mei and Liu, Guo-Qiang and Lin, Hong and Cai, Liang and Huang, Cai-Zhong and Mo, Gui-Qiong and Zhong, Xin-Jing},
  title = {Enhanced External Counterpulsation Reduces the Risk of Early Cystatin‐C Rise in STEMI Patients After Primary PCI: A Single‐Center Randomized Controlled Clinical Trial},
  journal = {Cardiovascular Therapeutics},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/cdr/4232591}
}
Kostenlos starten →